{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T14:10:08Z","timestamp":1747923008690,"version":"3.41.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-02949-1","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T13:33:24Z","timestamp":1747920804000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HIV-1 subtype distribution and drug resistance profiles among PLWHA with detectable viremia in Henan Province, China, 2023"],"prefix":"10.1038","volume":"15","author":[{"given":"Jinjin","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaohong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuguang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingxia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqi","family":"Huo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"2949_CR1","unstructured":"Infectious Diseases Branch of Chinese Medical Association, A.a.H.C.G.C.C.f.D.C.a.P., Chinese Guidelines for the Diagnosis and Treatment of AIDS (2021 Edition). . Medical Journal of Peking Union Medical College Hospital. 13(02): p. 203\u2013226 (2022)."},{"key":"2949_CR2","doi-asserted-by":"publisher","first-page":"S798","DOI":"10.1093\/infdis\/jix137","volume":"216","author":"C Godfrey","year":"2017","unstructured":"Godfrey, C. et al. Global HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation. J. Infect. Dis. 216, S798\u2013S800 (2017).","journal-title":"J. Infect. Dis."},{"key":"2949_CR3","unstructured":"The path that ends AIDS: UNAIDS Global AIDS Update 2023. Geneva: Joint United Nations Programme on HIV\/AIDS. (2023). Available at: https:\/\/www.unaids.org\/en\/resources\/documents\/2023\/global-aids-update-2023. (2023)."},{"key":"2949_CR4","doi-asserted-by":"crossref","unstructured":"Liu, J., Liu, C., Wang, Y. et al., Increased prevalence of pretreatment drug resistance mutations in treatment-na\u00efve people living with HIV-1 in Henan Province, China (2022\/23). Infection, genetics and evolution. 115: p. 105520 (2023).","DOI":"10.1016\/j.meegid.2023.105520"},{"issue":"2","key":"2949_CR5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/S1473-3099(17)30681-3","volume":"18","author":"LE Hermans","year":"2018","unstructured":"Hermans, L. E. et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. Lancet Infect Dis. 18(2), 188\u2013197 (2018).","journal-title":"Lancet Infect Dis."},{"key":"2949_CR6","doi-asserted-by":"crossref","unstructured":"Seth C, I., Silvia, B., Cissy M, K. et al., The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa. ADIS. 34(10): p. 1559\u20131566, (2020).","DOI":"10.1097\/QAD.0000000000002588"},{"key":"2949_CR7","doi-asserted-by":"crossref","unstructured":"Momo Kadia, B.A.-O., Takah, N.F., Akem Dimala, C. & Smith, A., Barriers to and enablers of uptake of and adherence to antiretroviral therapy in the context of integrated HIV and tuberculosis treatment among adults in sub-Saharan Africa: a protocol for a systematic literature review. BMJ Open. (28;9(10):e031789).","DOI":"10.1136\/bmjopen-2019-031789"},{"key":"2949_CR8","doi-asserted-by":"crossref","unstructured":"Zuo, L., Liu, K., Liu, H. et al., Corrigendum to \"Trend of HIV-1 drug resistance in China: A systematic review and meta-analysis of data accumulated over 17 years (2001\u20132017)\" [EClinicalMedicine 18 (2020) 100238]. EClinicalMedicine. 33(100696) (2021).","DOI":"10.1016\/j.eclinm.2020.100696"},{"key":"2949_CR9","doi-asserted-by":"crossref","unstructured":"Liu, J., Chen Z Fau - Wei, S., Wei S Fau - Ma, J. et al., Drug resistance mutations among people living with HIV with treatment failure in Henan Province, China. Chin. Med. J. (Engl). 136(2542\u20135641) (2023).","DOI":"10.1097\/CM9.0000000000002881"},{"issue":"11","key":"2949_CR10","first-page":"1795","volume":"44","author":"Y Xuan","year":"2023","unstructured":"Xuan, Y. et al. Characteristics of drug resistance in HIV\/AIDS patients with antiretroviral treatment failure in Henan Province. Chinese J. Epidemiol. 44(11), 1795\u20131801 (2023).","journal-title":"Chinese J. Epidemiol."},{"key":"2949_CR11","unstructured":"WHO, Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. (2021)."},{"issue":"12","key":"2949_CR12","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1093\/cid\/ciaa413","volume":"72","author":"E Olof","year":"2021","unstructured":"Olof, E. et al. All-Cause Mortality and Serious Non-AIDS Events in Adults With Low-level Human Immunodeficiency Virus Viremia During Combination Antiretroviral Therapy: Results From a Swedish Nationwide Observational Study. Clin. Infect Dis. 72(12), 2079\u20132086 (2021).","journal-title":"Clin. Infect Dis."},{"key":"2949_CR13","doi-asserted-by":"crossref","unstructured":"Appolonia, A., Sherri, P., Timothy, N. et al., Retrospective longitudinal analysis of low-level viremia among HIV-1 infected adults on antiretroviral therapy in Kenya. EClinicalMedicine. 63(0) (2023).","DOI":"10.1016\/j.eclinm.2023.102166"},{"key":"2949_CR14","doi-asserted-by":"crossref","unstructured":"Mirriam M, N., Cecilia N, W., James M, K.e. & Nancy L M, B., HIV Virologic Failure among Patients with Persistent Low-Level Viremia in Nairobi, Kenya: It Is Time to Review the >1000 Virologic Failure Threshold. .Biomed. Res. (2023).","DOI":"10.1155\/2023\/8961372"},{"key":"2949_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-60965-z","author":"L Jinjin","year":"2024","unstructured":"Jinjin, L. et al. Characteristics of drug resistance mutations in ART-experienced HIV-1 patients with low-level viremia in Zhengzhou City China. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-024-60965-z (2024).","journal-title":"Sci. Rep."},{"issue":"4","key":"2949_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.7326\/0003-4819-151-4-200908180-00006","volume":"151","author":"F Zhang","year":"2009","unstructured":"Zhang, F. et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. Annals Internal Med. 151(4), 241\u2013251 (2009).","journal-title":"Annals Internal Med."},{"issue":"10","key":"2949_CR17","doi-asserted-by":"publisher","first-page":"e110749","DOI":"10.1371\/journal.pone.0110749","volume":"9","author":"L Hofstra","year":"2014","unstructured":"Hofstra, L. et al. Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients. PLoS ONE 9(10), e110749 (2014).","journal-title":"PLoS ONE"},{"issue":"1","key":"2949_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1089\/aid.2014.0194","volume":"31","author":"G Sahu","year":"2015","unstructured":"Sahu, G. Potential implication of residual viremia in patients on effective antiretroviral therapy. AIDS Res. Hum. Retroviruses. 31(1), 25\u201335 (2015).","journal-title":"AIDS Res. Hum. Retroviruses."},{"issue":"1","key":"2949_CR19","doi-asserted-by":"publisher","first-page":"10620","DOI":"10.1038\/s41598-024-60965-z","volume":"14","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. Characteristics of drug resistance mutations in ART-experienced HIV-1 patients with low-level viremia in Zhengzhou City China. Sci. Rep. 14(1), 10620 (2024).","journal-title":"Sci. Rep."},{"issue":"9","key":"2949_CR20","first-page":"800","volume":"36","author":"E Yu","year":"2023","unstructured":"Yu, E. et al. HIV-1 Subtype Diversity and Factors Affecting Drug Resistance among Patients with Virologic Failure in Antiretroviral Therapy in Hainan Province, China, 2014\u20132020. Biomed. Environ. Sci. 36(9), 800\u2013813 (2023).","journal-title":"Biomed. Environ. Sci."},{"key":"2949_CR21","unstructured":"Qi, G., Hui, W., Xihui, Z. et al., Genotypic Drug Resistance Characteristics of HIV-1 Strains in HIV\/AIDS Patients with Failed Antiviral Therapy in Jilin Province Chinese Journal of Frontier Health and Quarantine. 46, 583\u2013588, (2023)."},{"issue":"3","key":"2949_CR22","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/jac\/dkad370","volume":"79","author":"M Zhang","year":"2024","unstructured":"Zhang, M. et al. The profile of HIV-1 drug resistance in Shanghai, China: a retrospective study from 2017 to 2021. J. Antimicrob Chemother. 79(3), 526\u2013530 (2024).","journal-title":"J. Antimicrob Chemother."},{"key":"2949_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ijid.2017.10.020","volume":"66","author":"S Karade","year":"2018","unstructured":"Karade, S. et al. HIV drug resistance following a decade of the free antiretroviral therapy programme in India: A review. Int. J. Infect. Dis. 66, 33\u201341 (2018).","journal-title":"Int. J. Infect. Dis."},{"issue":"7","key":"2949_CR24","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1093\/jac\/dkx095","volume":"72","author":"A Ntamatungiro","year":"2017","unstructured":"Ntamatungiro, A. et al. Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression. J. Antimicrob. Chemother. 72(7), 2069\u20132074 (2017).","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"2949_CR25","doi-asserted-by":"publisher","first-page":"e0257731","DOI":"10.1371\/journal.pone.0257731","volume":"17","author":"A Kirichenko","year":"2022","unstructured":"Kirichenko, A. et al. Prevalence of HIV-1 drug resistance in Eastern European and Central Asian countries. PLoS ONE 17(1), e0257731 (2022).","journal-title":"PLoS ONE"},{"key":"2949_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jgar.2023.07.013","volume":"35","author":"D Kapustin","year":"2023","unstructured":"Kapustin, D. et al. Patterns of HIV-1 drug resistance among HIV-infected patients receiving first-line antiretroviral therapy in Novosibirsk Region Russia. J. Glob. Antimicrobial Resist. 35, 1\u20135 (2023).","journal-title":"J. Glob. Antimicrobial Resist."},{"key":"2949_CR27","doi-asserted-by":"publisher","unstructured":"Patrick T, M., Wonderful T, C., Dorcas, M. et al., High prevalence of pre-treatment and acquired HIV-1 drug resistance mutations among non-citizens living with HIV in Botswana. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2024.1338191. (2024).","DOI":"10.3389\/fmicb.2024.1338191"},{"key":"2949_CR28","doi-asserted-by":"publisher","unstructured":"Nurjannah, Sri, J., Francisca Srioetami, T. et al., Major Drug Resistance Mutations on Reverse Transcriptase Gene in Human Immunodeficiency Virus Type-1 in Indonesia: A Systematic Review. Curr. HIV\/AIDS Rep. https:\/\/doi.org\/10.1007\/s11904-023-00687-5, (2024).","DOI":"10.1007\/s11904-023-00687-5"},{"issue":"7","key":"2949_CR29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1089\/aid.2020.0194","volume":"37","author":"R Sno","year":"2021","unstructured":"Sno, R., Labadie-Bracho, M., Gr\u00fcnberg, M. & Adhin, M. First Assessment of Acquired HIV-1 Drug Resistance and Mutation Patterns in Suriname. AIDS Res. Hum. Retro. 37(7), 557\u2013565 (2021).","journal-title":"AIDS Res. Hum. Retro."},{"issue":"22","key":"2949_CR30","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1097\/CM9.0000000000001473","volume":"135","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Prevalence of transmitted drug resistance mutations among patients infected with human immunodeficiency virus type 1 (HIV-1) in Henan Province China. Chinese Med. J. 135(22), 2750\u20132752 (2022).","journal-title":"Chinese Med. J."},{"issue":"6","key":"2949_CR31","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.1016\/S2352-3018(22)00092-3","volume":"9","author":"NI Paton","year":"2022","unstructured":"Paton, N. I. et al. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. Lancet HIV. 9(6), e381\u2013e393 (2022).","journal-title":"Lancet HIV."},{"issue":"4","key":"2949_CR32","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa2101609","volume":"385","author":"NI Paton","year":"2021","unstructured":"Paton, N. I. et al. Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV. N. Engl. J. Med. 385(4), 330\u2013341 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2949_CR33","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jgar.2019.08.024","volume":"20","author":"L Mazzuti","year":"2019","unstructured":"Mazzuti, L. et al. Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-na\u00efve patients: A single-centre experience. J Glob Antimicrob. Resist. 20, 298\u2013303 (2019).","journal-title":"J Glob Antimicrob. Resist."},{"key":"2949_CR34","doi-asserted-by":"crossref","unstructured":"Kempf, D. J. et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. 75(16), 7462\u20137469 (2021).","DOI":"10.1128\/JVI.75.16.7462-7469.2001"},{"issue":"6","key":"2949_CR35","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s15010-021-01668-9","volume":"49","author":"Z Yang","year":"2021","unstructured":"Yang, Z. et al. Prevalence of integrase strand transfer inhibitor (INSTIs) resistance mutations in Henan Province, China (2018\u20132020). Infection 49(6), 1195\u20131202 (2021).","journal-title":"Infection"},{"issue":"6","key":"2949_CR36","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1007\/s00705-020-04606-6","volume":"165","author":"Z Yang","year":"2020","unstructured":"Yang, Z. et al. Characterization of HIV-1 subtypes and drug resistance mutations in Henan Province, China (2017\u20132019). Arch. Virol. 165(6), 1453\u20131461 (2020).","journal-title":"Arch. Virol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02949-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02949-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02949-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T13:33:36Z","timestamp":1747920816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02949-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2949"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-02949-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"27 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17825"}}